Association of iron metabolism disorders with the development of prostate cancer

Abstract

Objective To investigate the relationship between iron metabolism disorder and the development and progression of prostate cancer. Methods From May 2014 to May 2017, 80 patients with prostate cancer in our hospital were selected as the experimental group, and 80 patients with benign prostatic hyperplasia were selected as the control group. The two groups were collected by centrifugation to separate blood serum, detect serum total prostate specific antigen (PSA), free prostate specific antigen (free PSA), serum ferritin levels and high blood protein in proportion. The expressions of Hepcidin, IL-6, soluable transferritin recptor(sTfR) and bone morphogenebic protein-6(BMP6) in serum of two groups were measured by ELISA method. Correlation between serum markers and prognostic factors, correlation between serum markers and risk of prostate cancer, and correlation between Hepcidin and variables were analyzed. Results There was no significant difference between the two groups in age (P>0.05), but compared with the patients with benign prostatic hyperplasia and prostate cancer patients serum ferritin, total PSA, free PSA and free PSA/and total PSA were significantly increased, the proportion of patients with high blood protein increased significantly (P<0.05). Gleason scores, total PSA levels and serum ferritin levels were positively correlated with patient stage, lymph node invasion, and distant metastasis in patients with prostate cancer. Elevated serum ferritin levels were significantly associated with elevated serum total PSA and increased prostate cancer risk (P<0.05). At the same time, high blood pressure was associated with elevated serum total PSA and risk of prostate cancer (P<0.05). The expression of Hepcidin, IL-6 and BMP6 in serum of patients with prostate cancer were significantly higher than those in patients with benign prostatic hyperplasia (P<0.05), the expression of sTfR was significantly lower than that of patients with benign prostatic hyperplasia (P<0.05), there was no significant difference in HB expression between the two groups (P<0.05). The expression of Hepcidin was positively correlated with the expression of IL-6 and BMP6 in prostate cancer patients, and negatively correlated with the expression of sTfR, which was not related to the expression of HB. The expression of Hepcidin was not correlated with the expression of IL-6, sTfR, BMP6 and HB in BPH patients. Conclusions The occurrence and development of prostate cancer can be predicted by detecting the expression of Hepcidin in serum and serum ferritin levels. Serum ferritin is positively correlated with pathological stage, lymph node invasion and distant metastasis of prostate cancer. Elevated serum ferritin levels increase the risk of prostate cancer. Key words: Prostatic Neoplasms; Iron Metabolism Disorders